EE88 Cost-Effectiveness of Apixaban Compared to Warfarin, Dabigatran and Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation: Results for High-Risk Patient Subgroups Based on the Aristophanes Real-World Evidence Study

Saved in:
Bibliographic Details
Published in:Value in health 2024-06, Vol.27 (6), p.S73-S74
Main Authors: Spalding, C, Mountford, B, Czarnota-Bojarski, S., Strakosch, T, Subash, R
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:1098-3015
1524-4733
DOI:10.1016/j.jval.2024.03.388